Shares surged 6.2% to $141.69 as investors digested a second quarter that cleared every bar Wall Street had set. Agilent posted non-GAAP earnings of $1.49 per share, up 13.7% year over year, beating the consensus estimate by 6.2%.
Revenue landed at $1.84 billion, a 10% jump, topping forecasts by roughly 2%. The real signal for shareholders was what came next: management used the beat to raise guidance for the rest of the year.
Every Business Line Grew, Not Just the Headline Number
All three segments expanded, led by Applied Markets (up 14%) and Life Sciences and Diagnostics (up 12%).
Recurring revenue from consumables, services, and software accounted for 66% of sales — the kind of repeat-purchase stream that makes earnings more predictable. Broad-based growth matters because it tells investors this wasn't a one-product quarter; the demand picture is wide.
Margins Expanded Thanks to Smarter Pricing and Cost Cuts
Non-GAAP operating margin hit 26.4%, expanding 130 basis points (about 1.3 percentage points) year over year and 180 basis points sequentially.
Strategic pricing actions contributed roughly 200 basis points to margins, while Agilent's internal efficiency program helped tighten cost discipline. Fatter margins mean more of each dollar of revenue drops to the bottom line — the clearest way a company grows profits faster than sales.
The Raised Outlook Puts Management's Credibility on the Line
Full-year revenue guidance was lifted to $7.39–$7.49 billion with non-GAAP EPS now expected at $6.00–$6.10, up $0.08 at the midpoint and representing 7%–9% growth.
Agilent also raised its operating margin expansion target to 85 basis points for fiscal 2026. That's the second consecutive quarter of upward revisions — after Q1, the EPS range stood at $5.90–$6.04 — signaling management sees durable demand rather than a pull-forward.
Open Questions Remain for the Second Half
Agilent still expects a low single-digit decline in academic and government spending , and the raised guidance excludes any impact from its pending Biocare acquisition or tariff refunds.
At $141.69, the stock sits about 15% below its 52-week high of $159.62 , suggesting the market is pricing in improvement but hasn't fully bought the recovery story. If Agilent delivers on the second half, today's pop could prove to be early innings. If macro headwinds stiffen, investors will want to see whether those margin gains stick without top-line help.